Melanoma A2058 cells were treated with frugoside in dose-dependent manner for 24 h. The stimulated cells using a flow cytometer were analyzed for mitochondrial function, such as membrane potential (A), mitochondrial ROS (B), and calcium overload (C). Mitochondrial membrane potential was measured using a FACScanto II after TMRE staining in A2058 cells treated with frugoside according to the dose. Mitochondrial ROS was measured in frugoside-treated melanoma cells via Mito-Sox staining. Mitochondrial calcium level was measured using a Rhod2-AM fluorescence dye and quantified. Values are presented as mean ± SDs. p values were derived to assess statistical significance and are indicated as follows: ** p < 0.01; and *** p < 0.001. Figure S5 . Accumulated ROS due to frugoside induces apoptotic cell death by sustained p38MAPK activation. (A) A375 cells were treated with frugoside in time-and dose-dependent manners. The cell lysates were subjected to western blotting with specific antibodies to phosphorylated MAPKs as indicated in the figure. The same membrane was re-probed with antibodies to the following MAPKs: JNK, p38MAPK, and ERK. (B) A375 cells were pretreated with 2 mM NAC or 10 μM DPI for 1 h, followed by 1 μg /mL frugoside for 24 h. The cells were subjected to FACS analysis after PI/Annexin V-FITC staining. (C) M14 cells were pretreated with 2 mM NAC or 10 μM DPI for 1 h, followed by 1 μg /mL frugoside for 24 h, and the cells were analyzed with a fluorescence microscope after TMRE staining. p values were derived to assess statistical significance and are indicated as follows: *** p < 0.001. Original magfication, 100×. Figure S8 . SRXN1 mRNA expression in normal and skin cutaneous melanoma (SKCM) based on TCGA and GTEx data in GEPIA. N, normal tissues; T, Tumor tissues. Number of samples indicated at the bottom, * p < 0.05, p-values between group were calculated using Welch's corrected t-test.
